UCB Ventures — 2022 Investments
1 investments dated 2022 · listed companies and verified rows first · show all
Switch Therapeutics develops RNA interference (RNAi) therapeutic applications targeting central nervous system diseases, leveraging research from Caltech, Harvard Medical School, and City of Hope.
AI & Machine LearningBiotechDeep TechMedical DevicesSouth San Francisco, US
Si-Ping Han(Secretary)Deepshikha Datta(Chief Executive Officer and President)
BoardKevin Zhang(Director)Dylan Morris(Director)
Board seatAlicia Irurzun-Lafitte· per SEC Form D · $36M raise · filed Nov 2022
Co-investorsBold Capital PartnersCRV (Charles River Ventures)FREEFLOWGlobal BrainOno Venture Investment, Inc.Upfront Ventures+2 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.